Sold by: Sage Bionetworks
Open data
|
Deployed on AWS
The Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) Diverse
Cohorts Study is a cross-consortium project generating harmonized datasets
from diverse human cohorts. It provides post-mortem multi-omic data from more
than 850 individuals representing the spectrum of Alzheimer's disease
phenotypes, with substantial representation of Black or African American and
Hispanic or Latino individuals. Data were generated by research teams at Rush
University, Emory University, Mayo Clinic, Columbia University, and the Icahn
School of Medicine at Mount Sinai.
Overview
The Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) Diverse Cohorts Study is a cross-consortium project generating harmonized datasets from diverse human cohorts. It provides post-mortem multi-omic data from more than 850 individuals representing the spectrum of Alzheimer's disease phenotypes, with substantial representation of Black or African American and Hispanic or Latino individuals. Data were generated by research teams at Rush University, Emory University, Mayo Clinic, Columbia University, and the Icahn School of Medicine at Mount Sinai.
Features and programs
Open Data Sponsorship Program
This dataset is part of the Open Data Sponsorship Program, an AWS program that covers the cost of storage for publicly available high-value cloud-optimized datasets.
Pricing
This is a publicly available data set. No subscription is required.
Legal
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Open data resources
Available with or without an AWS account.
- How to use
- To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more
- Description
- This study provides controlled-access post-mortem brain multi-omic data, including whole-genome sequencing, bulk RNA sequencing, proteomics, single-nucleus gene expression and chromatin accessibility data, and harmonized clinical and neuropathology metadata from diverse cohorts.
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::amp-ad-diverse-cohorts.opendata.sagebase.org
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://amp-ad-diverse-cohorts.opendata.sagebase.org/
Resources
Vendor resources
Support
Managed By
Sage Bionetworks
How to cite
Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) Diverse Cohorts Study was accessed on DATE from https://registry.opendata.aws/amp-ad-diverse-cohorts .
Similar products
The Whole Genome Sequence Harmonization Study provides uniformly processed
whole-genome sequencing data generated from the three primary AMP-AD cohort
studies: the Religious Orders Study and Memory and Aging Project (ROSMAP),
the Mount Sinai Brain Bank (MSBB), and the Mayo RNAseq Study. The project
harmonizes whole-genome sequence data across these cohorts to support
cross-study analyses of genomic variation associated with aging,
Alzheimer's disease, and related dementias.
Identify risk of being diagnosed with Alzheimers
A structured engagement that moves agentic AI from pilot to production on AWS for healthcare organizations, with built-in governance, security, and compliance for regulated workloads.
The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are
ongoing longitudinal clinical-pathologic cohort studies of aging and
Alzheimer's disease. Participants enroll without known dementia, undergo
annual clinical and cognitive evaluations, and agree to organ donation at
death. The ROSMAP study provides genomic, transcriptomic, epigenomic,
proteomic, metabolomic, imaging, and related metadata generated from these
cohorts to support research into cognitive decline, neuropathology, brain
aging, and the molecular mechanisms of Alzheimer's disease.